Hisato Kawakami

List of Publications by Year
in descending order

109 papers	3,488 citations	201385 27 h-index	155451 55 g-index
111 all docs	111 docs citations	111 times ranked	5012 citing authors

#	Article	IF	Citations
1	Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapyâ€induced colitis. Molecular Oncology, 2022, 16, 1493-1507.	2.1	17
2	Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08). Gastric Cancer, 2022, 25, 235-244.	2.7	17
3	Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. Esophagus, 2022, 19, 137-145.	1.0	8
4	OUP accepted manuscript. Oncologist, 2022, 27, 251-e304.	1.9	1
5	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2â€“positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).. Journal of Clinical Oncology, 2022, 40, 242-242.	0.8	5
6	Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 322-322.	0.8	3
7	Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer: A Phase II Study (OGSG 1107). Gastrointestinal Tumors, 2022, 9, 27-36.	0.3	0
8	HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2022, 28, 390-403.	3.2	34
9	Phase <scp>IIb</scp> study of pembrolizumab combined with Sâ€Â+â€‰oxaliplatin or Sâ€Â+â€‰cisplatin as firstâ€line chemotherapy forÂgastric cancer. Cancer Science, 2022, 113, 2814-2827.	1.7	10
10	Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus Sâ€‰â^'â€‰1 therapy. BMC Cancer, 2022, 22, .	1.1	1
11	REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer. Future Oncology, 2021, 17, 869-875.	1.1	6
12	Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3). Esophagus, 2021, 18, 90-99.	1.0	30
13	Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3). Gastric Cancer, 2021, 24, 428-434.	2.7	7
14	Phase II Study of Panitumumab Monotherapy in Chemotherapy-NaÃ¯ve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602. Oncologist, 2021, 26, 17-e47.	1.9	13
15	Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 1-25.	1.4	29
16	Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. British Journal of Cancer, 2021, 124, 914-924.	2.9	37
17	Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors. Oncologist, 2021, 26, e588-e596.	1.9	48
18	FMSâ€like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer Science, 2021, 112, 314-322.	1.7	8

#	Article	IF	Citations
19	A phase II study of perioperative capecitabine plus oxaliplatin for clinical SS/SE N1-3 M0 gastric cancer (OGSG1601).. Journal of Clinical Oncology, 2021, 39, 203-203.	0.8	0
20	Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).. Journal of Clinical Oncology, 2021, 39, 161-161.	0.8	17
21	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instabilityâ€"High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT,) Tj ETQq1 1 0.784314 rgBT /Overlock	1.1	11
22	Phase II study of panitumumab monotherapy in chemotherapy-naÃ¯ve frail or elderly patients with unresectable, RAS wild type colorectal cancer: OGSG 1602, survival update data.. Journal of Clinical Oncology, 2021, 39, 3558-3558.	0.8	0
23	Randomized phase II study comparing docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma who are refractory to fluoropyrimidine and platinum-based chemotherapy: OGSG1201.. Journal of Clinical Oncology, 2021, 39, 4037-4037.	0.8	0
24	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	5.1	234
25	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).. Journal of Clinical Oncology, 2021, 39, 3505-3505.	0.8	16
26	Folate receptor Î± increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAbâ€202 in gastric cancer. Clinical and Translational Medicine, 2021, 11, e454.	1.7	11
27	Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant Sâ€1 chemotherapy after gastrectomy: A multicenter, openâ€label, singleâ€arm, prospective phase II study (OGSG1108). Annals of Gastroenterological Surgery, 2021, 5, 776-784.	1.2	9
28	Serum lactate dehydrogenase is a predictive biomarker in patients with oropharyngeal cancer undergoing radiotherapy: Retrospective study on predictive factors. Head and Neck, 2021, 43, 3132-3141.	0.9	7
29	Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701. International Journal of Clinical Oncology, 2021, 26, 1871-1880.	1.0	1
30	KRAS Inhibitor Resistance in MET-Amplified KRASG12C Nonâ€"Small Cell Lung Cancer Induced By RAS- and Nonâ€"RAS-Mediated Cell Signaling Mechanisms. Clinical Cancer Research, 2021, 27, 5697-5707.	3.2	42
31	Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201. European Journal of Cancer, 2021, 154, 307-315.	1.3	4
32	Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC.. Journal of Clinical Oncology, 2021, 39, 120-120.	0.8	1
33	A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1â€3 M0 Gastric Cancer (OGSG 1601). Oncologist, 2020, 25, 119.	1.9	10
34	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nature Medicine, 2020, 26, 1859-1864.	15.2	209
35	A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood. Case Reports in Oncology, 2020, 13, 843-848.	0.3	1
36	A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302). International Journal of Clinical Oncology, 2020, 25, 2035-2043.	1.0	5

#	Article	IF	Citations
37	Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model. Journal of Clinical Medicine, 2020, 9, 4050.	1.0	2
38	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine, 2020, 382, 2419-2430.	13.9	681
39	Comparison of S-1â€“cisplatin every 5Âweeks with capecitabine-cisplatin every 3Âweeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naÃ¯ve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials. International Journal of Clinical Oncology, 2020, 25, 1635-1643.	1.0	7
40	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. European Journal of Cancer, 2020, 129, 97-106.	1.3	48
41	Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer. In Vivo, 2020, 34, 1921-1929.	0.6	9
42	Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. Cancers, 2020, 12, 400.	1.7	50
43	Phase II study of 5-fluorouracilâ€“leucovorin plus bevacizumab for chemotherapy-naÃ¯ve older or frail patients with metastatic colorectal cancer (OGSG 0802). International Journal of Clinical Oncology, 2020, 25, 1291-1298.	1.0	5
44	A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.. Journal of Clinical Oncology, 2020, 38, 4000-4000.	0.8	48
45	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).. Journal of Clinical Oncology, 2020, 38, 4513-4513.	0.8	7
46	Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.. Journal of Clinical Oncology, 2020, 38, 4071-4071.	0.8	0
47	DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer. Future Oncology, 2019, 15, 2441-2447.	1.1	7
48	Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer. Annals of Oncology, 2019, 30, v231-v232.	0.6	2
49	A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. Scientific Reports, 2019, 9, 11340.	1.6	12
50	Clinical and immune profiling for cancer of unknown primary site. , 2019, 7, 251.		26
51	Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. Oncogenesis, 2019, 8, 54.	2.1	12
52	Targeting of the HER2/HER3 signaling axis overcomes ligandâ€mediated resistance to trastuzumab in HER2â€positive breast cancer. Cancer Medicine, 2019, 8, 1258-1268.	1.3	54
53	[famâ€] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. International Journal of Cancer, 2019, 145, 3414-3424.	2.3	62
54	Phase II Trial of 5â€Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer. Oncologist, 2019, 24, 163.	1.9	10

#	Article	IF	Citations
55	Mutational activation of the epidermal growth factor receptor downâ€regulates major histocompatibility complex class I expression via the extracellular signalâ€regulated kinase in nonâ€“small cell lung cancer. Cancer Science, 2019, 110, 52-60.	1.7	31
56	An HER3-targeting antibodyâ€“drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. Oncogene, 2019, 38, 1398-1409.	2.6	69
57	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. Journal of Clinical Investigation, 2019, 130, 374-388.	3.9	43
58	Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15106-e15106.	0.8	1
59	Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.. Journal of Clinical Oncology, 2019, 37, 578-578.	0.8	1
60	REVIVE study: Prospective observational study of efficacy and safety in chemotherapy (CTx) after progressive disease of nivolumab (NIV) therapy for metastatic gastric cancer (mGC).. Journal of Clinical Oncology, 2019, 37, TPS178-TPS178.	0.8	0
61	A dose-finding study for irinotecan, cisplatin, and S-1 (IPS) in patients with advanced gastric cancer (OGSG 1106).. Journal of Clinical Oncology, 2019, 37, 144-144.	0.8	0
62	Abstract 1668: A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing. , 2019, , .		0
63	Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. Investigational New Drugs, 2018, 36, 726-731.	1.2	17
64	Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. Molecular Cancer Research, 2018, 16, 378-389.	1.5	99
65	Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-NaÃ¯ve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial. Oncologist, 2018, 23, 1411-e147.	1.9	15
66	Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC. Journal of Thoracic Oncology, 2018, 13, e239-e241.	0.5	17
67	Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 624-624.	0.8	1
68	Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR).. Journal of Clinical Oncology, 2018, 36, 670-670.	0.8	4
69	Two-step Intensity-modulated Radiation Therapy for Oropharyngeal Cancer: Initial Clinical Experience and Validation of Clinical Staging. Anticancer Research, 2018, 38, 979-986.	0.5	4
70	Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naÃ¯ve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial.. Journal of Clinical Oncology, 2018, 36, 102-102.	0.8	0
71	The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.. Journal of Clinical Oncology, 2018, 36, TPS885-TPS885.	0.8	0
72	Abstract 2336: Targeting CDK1 and MEK/ERK overcomes apoptosis resistance in BRAFV600E human colorectal cancer cells. , 2018, , .		0

#	Article	IF	Citations
73	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investigational New Drugs, 2017, 35, 529-536.	1.2	128
74	T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Nonâ€“Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 2563-2571.	1.9	19
75	Abstract 2173: Targeting CDK1 and MEK/ERK overcome mutantBRAF-mediated apoptosis resistance in human colorectal cancer cells. , 2017, , .		1
76	Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. Oncotarget, 2017, 8, 80286-80294.	0.8	9
77	Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 603-603.	0.8	0
78	Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. Oncotarget, 2016, 7, 84860-84871.	0.8	18
79	Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Investigational New Drugs, 2016, 34, 347-354.	1.2	57
80	Sa1808 Mutant BRAF (V600E) Phosphorylates MCL-1 to Increase Stability/Expression That Confers Apoptosis Resistance in Colorectal Cancer Cells. Gastroenterology, 2016, 150, S372.	0.6	0
81	Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Molecular Cancer Therapeutics, 2016, 15, 3015-3027.	1.9	36
82	Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2016, 14, 651-658.	2.4	99
83	MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer, 2016, 19, 687-695.	2.7	37
84	HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy. Recent Patents on Anti-Cancer Drug Discovery, 2016, 11, 267-274.	0.8	25
85	Abstract 2939: Heregulin-induced resistance against HER2-targeted therapies in HER2 positive breast and gastric cancer in vitro and in vivo. , 2016, , .		0
86	Abstract 2115: MEK/ERK and MCL-1 inhibition synergistically reverse apoptosis resistance in colon cancer cells with BRAF(V600E)-mediated MCL-1-upregulation. , 2016, , .		0
87	Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer. Current Treatment Options in Oncology, 2015, 16, 30.	1.3	309
88	Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. Molecular Cancer Research, 2015, 13, 659-669.	1.5	22
89	49 Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Bcl-xL Antagonism and Induction of Pro-Apoptotic BH3-Only Proteins in Colorectal Carcinoma Cells. Gastroenterology, 2015, 148, S-15.	0.6	0
90	The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. Journal of Biological Chemistry, 2015, 290, 23838-23849.	1.6	46

#	Article	IF	Citations
91	Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 279-285.	1.1	4
92	Abstract 2937: MEK/ERK inhibitor GDC-0623 dephosphorylates and accumulates BIM that enables a synergistic apoptosis with the Bcl-xL antagonist, ABT-263, in mutantKRAScolorectal cancer cells. , 2015, , .		1
93	Implications of mismatch repair-deficient status on management of early stage colorectal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 676-84.	0.6	49
94	The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget, 2014, 5, 11847-11856.	0.8	61
95	Heregulin as a Biomarker for Anti-Her3 Antibody Patritumab Combined with Erlotinib in Non-Small Cell Lung Cancer. Annals of Oncology, 2014, 25, v73.	0.6	0
96	Clinical Benefit of Continued Therapy with Crizotinib Beyond Initial Disease Progression in Advanced Alk Positive Nsclc. Annals of Oncology, 2014, 25, v70.	0.6	0
97	Targeting MET Amplification as a New Oncogenic Driver. Cancers, 2014, 6, 1540-1552.	1.7	96
98	Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection. PLoS ONE, 2014, 9, e101902.	1.1	106
99	Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer. Investigational New Drugs, 2014, 32, 946-954.	1.2	10
100	The expression level of HER3 ligand heregulin mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer.. Journal of Clinical Oncology, 2014, 32, e19082-e19082.	0.8	2
101	Abstract 1844: Novel HER3 neutralizing antibody, patritumab abrogates cetuximab resistance mediated by a heregulin-autocrine loop in colorectal cancer. , 2014, , .		0
102	Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. European Journal of Cancer, 2013, 49, 3003-3009.	1.3	16
103	Phase <scp>I</scp> trial of <scp>OTS</scp>11101, an antiâ€angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor. Cancer Science, 2013, 104, 98-104.	1.7	14
104	Human papillomavirus DNA and p16 expression in J apanese patients with oropharyngeal squamous cell carcinoma. Cancer Medicine, 2013, 2, 933-941.	1.3	27
105	MET amplification as a potential therapeutic target in gastric cancer. Oncotarget, 2013, 4, 9-17.	0.8	82
106	Abstract 4657: MET amplification as a potential therapeutic target in gastric cancer.. , 2013, , .		0
107	Phase I dose finding study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, alone or in combination with paclitaxel in Japanese patients.. Journal of Clinical Oncology, 2013, 31, e13501-e13501.	0.8	0
108	Pharmacokinetics (PK) and Safety of Tesetaxel, a Novel Oral Taxane, in Japanese Patients (PTS) with Advanced Solid Tumors. Annals of Oncology, 2012, 23, ix167.	0.6	1

#	Article	IF	Citations
109	Human Epidermal Growth Factor Eyedrops for Cetuximab-Related Filamentary Keratitis. Journal of Clinical Oncology, 2011, 29, e678-e679.	0.8	14